Annual Accounts Receivable
$2.63 M
+$2.28 M+657.35%
31 December 2023
Summary:
Celldex Therapeutics annual accounts receivable is currently $2.63 million, with the most recent change of +$2.28 million (+657.35%) on 31 December 2023. During the last 3 years, it has risen by +$826.00 thousand (+45.84%). CLDX annual accounts receivable is now -16.89% below its all-time high of $3.16 million, reached on 31 December 2018.CLDX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$852.00 K
-$682.00 K-44.46%
01 September 2024
Summary:
Celldex Therapeutics quarterly accounts receivable is currently $852.00 thousand, with the most recent change of -$682.00 thousand (-44.46%) on 01 September 2024. Over the past year, it has increased by +$600.00 thousand (+238.10%). CLDX quarterly accounts receivable is now -92.58% below its all-time high of $11.48 million, reached on 30 September 2008.CLDX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +657.4% | +238.1% |
| 3 y3 years | +45.8% | +332.5% |
| 5 y5 years | -16.9% | +17.2% |
CLDX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +1427.9% | -68.1% | +778.4% |
| 5 y | 5 years | -16.9% | +1427.9% | -68.1% | +778.4% |
| alltime | all time | -16.9% | +5872.7% | -92.6% | +7000.0% |
Celldex Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $852.00 K(-44.5%) |
| June 2024 | - | $1.53 M(-42.6%) |
| Mar 2024 | - | $2.67 M(+1.6%) |
| Dec 2023 | $2.63 M(+657.3%) | $2.63 M(+942.9%) |
| Sept 2023 | - | $252.00 K(+113.6%) |
| June 2023 | - | $118.00 K(-91.0%) |
| Mar 2023 | - | $1.31 M(+278.7%) |
| Dec 2022 | $347.00 K(+101.7%) | $347.00 K(+83.6%) |
| Sept 2022 | - | $189.00 K(+94.8%) |
| June 2022 | - | $97.00 K(-60.1%) |
| Mar 2022 | - | $243.00 K(+41.3%) |
| Dec 2021 | $172.00 K(-90.5%) | $172.00 K(-12.7%) |
| Sept 2021 | - | $197.00 K(-60.3%) |
| June 2021 | - | $496.00 K(-72.9%) |
| Mar 2021 | - | $1.83 M(+1.4%) |
| Dec 2020 | $1.80 M(+77.5%) | $1.80 M(+115.0%) |
| Sept 2020 | - | $838.00 K(+154.7%) |
| June 2020 | - | $329.00 K(-70.3%) |
| Mar 2020 | - | $1.11 M(+9.2%) |
| Dec 2019 | $1.01 M(-67.9%) | $1.01 M(+39.6%) |
| Sept 2019 | - | $727.00 K(-37.9%) |
| June 2019 | - | $1.17 M(-49.3%) |
| Mar 2019 | - | $2.31 M(-27.0%) |
| Dec 2018 | $3.16 M(+68.2%) | $3.16 M(-0.4%) |
| Sept 2018 | - | $3.17 M(-7.2%) |
| June 2018 | - | $3.42 M(-14.9%) |
| Mar 2018 | - | $4.02 M(+113.8%) |
| Dec 2017 | $1.88 M(+5.4%) | $1.88 M(-37.6%) |
| Sept 2017 | - | $3.01 M(+121.7%) |
| June 2017 | - | $1.36 M(-1.8%) |
| Mar 2017 | - | $1.38 M(-22.4%) |
| Dec 2016 | $1.78 M(+83.9%) | $1.78 M(+13.0%) |
| Sept 2016 | - | $1.58 M(+41.5%) |
| June 2016 | - | $1.12 M(+31.8%) |
| Mar 2016 | - | $847.00 K(-12.7%) |
| Dec 2015 | $970.00 K(+127.2%) | $970.00 K(+84.1%) |
| Sept 2015 | - | $527.00 K(+21.4%) |
| June 2015 | - | $434.00 K(-36.1%) |
| Mar 2015 | - | $679.00 K(+59.0%) |
| Dec 2014 | $427.00 K(-12.7%) | $427.00 K(-85.3%) |
| Sept 2014 | - | $2.90 M(+453.3%) |
| June 2014 | - | $525.00 K(+72.1%) |
| Mar 2014 | - | $305.00 K(-37.6%) |
| Dec 2013 | $489.00 K | $489.00 K(-45.1%) |
| Sept 2013 | - | $890.00 K(+7316.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2013 | - | $12.00 K(-88.5%) |
| Mar 2013 | - | $104.00 K(+136.4%) |
| Dec 2012 | $44.00 K(-74.1%) | $44.00 K(-27.9%) |
| June 2012 | - | $61.00 K(-64.1%) |
| Dec 2011 | $170.00 K(-90.7%) | $170.00 K(-16.7%) |
| Sept 2011 | - | $204.00 K(-16.0%) |
| Mar 2011 | - | $243.00 K(-46.7%) |
| Sept 2010 | - | $456.00 K(-38.2%) |
| June 2010 | - | $738.00 K(-14.1%) |
| Mar 2010 | - | $859.00 K(-21.3%) |
| Sept 2009 | - | $1.09 M(+7.7%) |
| June 2009 | - | $1.01 M(-6.0%) |
| Mar 2009 | - | $1.08 M(-41.0%) |
| Dec 2008 | $1.83 M(+894.0%) | $1.83 M(-84.1%) |
| Sept 2008 | - | $11.48 M(+646.5%) |
| June 2008 | - | $1.54 M(+3843.6%) |
| Mar 2008 | - | $39.00 K(-28.4%) |
| Sept 2007 | - | $54.50 K(-46.8%) |
| June 2007 | - | $102.40 K(-57.1%) |
| Mar 2007 | - | $238.60 K(+29.8%) |
| Dec 2006 | $183.80 K(-56.1%) | $183.80 K(-66.8%) |
| Sept 2006 | - | $554.40 K(-24.6%) |
| June 2006 | - | $735.70 K(+2.7%) |
| Mar 2006 | - | $716.20 K(+71.2%) |
| Dec 2005 | $418.40 K(-81.2%) | $418.40 K(-92.6%) |
| Sept 2005 | - | $5.64 M(+3.0%) |
| June 2005 | - | $5.48 M(+497.6%) |
| Mar 2005 | - | $916.50 K(-58.9%) |
| Dec 2004 | $2.23 M(+51.4%) | $2.23 M(+262.2%) |
| Sept 2004 | - | $615.80 K(+14.0%) |
| June 2004 | - | $540.10 K(-67.3%) |
| Mar 2004 | - | $1.65 M(+12.2%) |
| Dec 2003 | $1.47 M(+537.9%) | $1.47 M(+159.1%) |
| Sept 2003 | - | $568.50 K(-3.0%) |
| June 2003 | - | $585.80 K(-7.7%) |
| Mar 2003 | - | $634.50 K(+174.8%) |
| Dec 2002 | $230.90 K(-13.6%) | $230.90 K(-89.1%) |
| Sept 2002 | - | $2.12 M(+847.9%) |
| June 2002 | - | $224.10 K(-1.5%) |
| Mar 2002 | - | $227.50 K(-14.9%) |
| Dec 2001 | $267.20 K(-38.1%) | $267.20 K(+65.4%) |
| Sept 2001 | - | $161.50 K(-57.9%) |
| June 2001 | - | $383.50 K(+119.1%) |
| Mar 2001 | - | $175.00 K(-59.5%) |
| Dec 1999 | $431.70 K | $431.70 K |
FAQ
- What is Celldex Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Celldex Therapeutics?
- What is Celldex Therapeutics annual accounts receivable year-on-year change?
- What is Celldex Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly accounts receivable year-on-year change?
What is Celldex Therapeutics annual accounts receivable?
The current annual accounts receivable of CLDX is $2.63 M
What is the all time high annual accounts receivable for Celldex Therapeutics?
Celldex Therapeutics all-time high annual accounts receivable is $3.16 M
What is Celldex Therapeutics annual accounts receivable year-on-year change?
Over the past year, CLDX annual accounts receivable has changed by +$2.28 M (+657.35%)
What is Celldex Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of CLDX is $852.00 K
What is the all time high quarterly accounts receivable for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly accounts receivable is $11.48 M
What is Celldex Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, CLDX quarterly accounts receivable has changed by +$600.00 K (+238.10%)